Tips on scheduling in-office meetings in legislators’ home districts and which issues to discuss
Why Tweaking Molecular Structures Can Be Hazardous to Our Health
The rise and fall of rofecoxib and valdecoxib demonstrate the need for caution in new drug development
Rheumatology Drug Updates, Trials, Safety Data
Information on oral anticoagulant apixaban, apremilast for active psoriatic arthritis, hyaluronic acid and methotrexate injections, and drug safety updates rheumatologists need to know
Ethics Forum: The Challenge of Multidisciplinary Care in Rheumatology
A patient with autoimmune ocular disease raises concerns about the moral, professional obligations of rheumatologists to help patients whose condition is not clearly within the scope of rheumatology
Recipients of Ephraim P. Engleman Endowed Resident Research Preceptorship Award in Rheumatology Meet Physician Who Helped Shape Their Careers
Award’s namesake, 103-year-old rheumatologist Ephraim P. Engleman, MD, met 10 winners of research funding established in his name by the Rheumatology Research Foundation in 2006
Fellow’s Forum Case Report: Takayasu’s Arteritis
How this rare form of large-vessel vasculitis affects different portions, branches of aorta and ways to diagnose, treat and manage the disease
Rheumatology Drug Updates, Trials, Safety Data
Information on acetaminophen restrictions; trials for clazakizumab, epratuzumab, romosozumab; and drug safety updates rheumatologists need to know
Tips for Treating Pain, Depression in Patients with Rheumatic Disease Offered at the ACR/ARHP’s 2013 Annual Meeting
Observational pain scales, diagnostic tools, pharmacologic interventions, and support from psychologists, caregivers recommended
Global Perspectives on Managing Rheumatoid Arthritis Addressed at the 2013 ACR/ARHP Annual Meeting
Poverty, poor access to healthcare, cultural myths present challenges for rheumatologists caring for patients with RA in developing economic regions
Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
Therapy with tumor necrosis factor inhibitors, nonsteroidal antiinflammatory drugs, ustekinumab in early stages of osteitis may halt molecular switching to bone-forming phenotype characteristic of SpA
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 21
- Next Page »